Top

Osteoporosis International

Published in:

01-08-2009 | Original Article

Changes in 25-Hydroxyvitamin D3 to oral treatment with vitamin D3 in postmenopausal females with osteoporosis

Authors: H. C. Hoeck, B. Li, P. Qvist

Published in: Osteoporosis International | Issue 8/2009

Abstract

Summary

This study reports on oral treatment with different doses of vitamin D3 ranging from 25 to 200 µg in females with 25-hydroxyvitamin D3 levels < 60 nmol/L screened for participation in an osteoporosis trial. A guidance to safely and efficiently achieve 25-hydroxyvitamin D3 levels > 60 nmol/L is presented.

Introduction

The importance of vitamin D for skeletal health has been implemented in clinical trials in osteoporosis. The threshold of 25-hydroxyvitamin D for inclusion has changed from 30 to 60 nmol/L. This study reports on oral treatment with different doses of vitamin D3 in females with 25-hydroxyvitamin D3 levels < 60 nmol/L.

Methods

In 131 postmenopausal females screened for participation in an osteoporosis trial, the 25-hydroxyvitamin D3 concentration was < 60 nmol/L. They were treated with 25 (n = 22), 50 (n = 19), 75 (n = 19), 100 (n = 41) or 200 μg (n = 30) of vitamin D3 daily for at least 10 days.

Results

In the females treated with 25, 50, 75, 100 and 200 μg of vitamin D3 daily the 25-hydroxyvitamin D3 concentrations increased significantly from 32.4 ± 2.7 (mean ± SEM) to 50.8 ± 2.9, from 46.7 ± 2.8 to 65.8 ± 2.6, from 41.6 ± 2.7 to 67.4 ± 2.9, from 46.7 ± 1.4 to 64.4 ± 2.2 and from 42.1 ± 2.0 to 71.2 ± 2.8 nmol/L, respectively (p < 0.001). S-calcium increased significantly but within the reference range (p < 0.006).

Conclusion

Oral vitamin D3 safely increased 25-hydroxyvitamin D3 concentrations in all females above 60 nmol/L. This study demonstrates how to achieve the new recommended 25-hydroxyvitamin D concentrations within the screening period of a clinical trial.

Zerwekh JE (2008) Blood biomarkers of vitamin D status. Am J Clin Nutr 87(4):1087S–1091SPubMed

Dawson-Hughes B, Heaney RP, Holick MF et al (2005) Estimates of optimal vitamin D status. Osteoporos Int 16(7):713–716PubMedCrossRef

Hollis BW, Wagner CL (2005) Normal serum vitamin D levels. N Engl J Med 352(5):515–516PubMedCrossRef

Chapuy MC, Preziosi P, Maamer M et al (1997) Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7(5):439–443PubMedCrossRef

Need AG, Horowitz M, Morris HA et al (2000) Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. Am J Clin Nutr 71(6):1577–1581PubMed

Sahota O, Mundey MK, San P et al (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35(1):312–319PubMedCrossRef

Heaney RP (2005) The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97(1–2):13–19PubMedCrossRef

Bischoff-Ferrari HA, Dietrich T, Orav EJ et al (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116(9):634–639PubMedCrossRef

Lips P, Duong T, Oleksik A et al (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86(3):1212–1221PubMedCrossRef

10.

Lappe JM, Davies KM, Travers-Gustafson D et al (2006) Vitamin D status in a rural postmenopausal female population. J Am Coll Nutr 25(5):395–402PubMed

11.

Smith JE, Goodman DS (1971) The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J Clin Invest 50(10):2159–2167PubMedCrossRef

12.

Vieth R, Chan PC, MacFarlane GD (2001) Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73(2):288–294PubMed

13.

Heaney RP, Armas LA, Shary JR et al (2008) 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr 87(6):1738–1742PubMed

14.

Trang HM, Cole DE, Rubin LA et al (1998) Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 68(4):854–858PubMed

15.

Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87(4):1080S–1086SPubMed

16.

Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135(2):317–322PubMed

17.

Harris SS, Dawson-Hughes B (2002) Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3. J Am Coll Nutr 21(4):357–362PubMed

18.

Geller JL, Hu B, Reed S et al (2008) Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Endocr Pract 14(3):293–297PubMed

19.

Heckman GA, Papaioannou A, Sebaldt RJ et al (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6, doi:10.1186/1471-2474-3-6 PubMedCrossRef

20.

Malabanan A, Veronikis IE, Holick MF (1998) Redefining vitamin D insufficiency. Lancet 351(9105):805–806PubMedCrossRef

21.

Lips P, Chapuy MC, Dawson-Hughes B et al (1999) An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 9(5):394–397PubMedCrossRef

22.

Binkley N, Krueger D, Cowgill CS et al (2004) Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89(7):3152–3157PubMedCrossRef

23.

Holick MF, Siris ES, Binkley N et al (2005) Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90(6):3215–3224PubMedCrossRef

24.

Pepe J, Romagnoli E, Nofroni I et al (2005) Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int 16(7):805–812PubMedCrossRef

25.

Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89(11):5387–5391PubMedCrossRef

26.

Houghton LA, Vieth R (2006) The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 84(4):694–697PubMed

27.

Holick MF, Biancuzzo RM, Chen TC et al (2008) Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93(3):677–681PubMedCrossRef

28.

Gordon CM, Williams AL, Feldman HA et al (2008) Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab 93(7):2716–2721PubMedCrossRef

29.

Hollis BW (2004) Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 89(7):3149–3151PubMedCrossRef

30.

Hypponen E, Power C (2007) Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 85(3):860–868PubMed

31.

Arunabh S, Pollack S, Yeh J et al (2003) Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 88(1):157–161PubMedCrossRef

32.

Prosser DE, Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29(12):664–673PubMedCrossRef

33.

Clemens TL, Zhou XY, Myles M et al (1986) Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab 63(3):656–660PubMedCrossRef

34.

Ernst B, Thurnheer M, Schmid SM, et al (2008) Seasonal Variation in the Deficiency of 25-Hydroxyvitamin D(3) in Mildly to Extremely Obese Subjects. Obes Surg doi:10.1007/s11695-008-9636-2

Title: Changes in 25-Hydroxyvitamin D3 to oral treatment with vitamin D3 in postmenopausal females with osteoporosis
Authors: H. C. Hoeck
B. Li
P. Qvist
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 8/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-008-0790-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in 25-Hydroxyvitamin D3 to oral treatment with vitamin D3 in postmenopausal females with osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2009

Bone microdamage: a clinical perspective

Thinking inside and outside the envelopes of bone

Bone turnover in age-related osteoporosis: early contributions of Pierre Delmas

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study

Which water for alendronate administration?

Teriparatide in men: persistence and geographical variation in the UK